The Feasibility of an Educational and Monitoring Smart-Phone Application for Patients With Advanced Renal Cell Carcinoma Undergoing Combination Immunotherapy

H. Lee Moffitt Cancer Center and Research Institute1 site in 1 country20 target enrollmentOctober 19, 2022

ConditionsRenal Cell Carcinoma Stage IV

Overview

Phase: N/A
Intervention: Not specified
Conditions: Renal Cell Carcinoma Stage IV
Sponsor: H. Lee Moffitt Cancer Center and Research Institute
Enrollment: 20
Locations: 1
Primary Endpoint: Acceptability of Smart Phone Application
Status: Completed
Last Updated: 4 months ago

Overview Investigators Eligibility Criteria Outcomes Sites Similar Trials

Overview

Brief Summary

The purpose of the study is to test and understand acceptability and preliminary effectiveness of a mobile educational app specifically customized to patients with advanced Renal Cell Carcinoma (RCC) receiving therapy with combination immunotherapy.

Registry

clinicaltrials.gov

Start Date

October 19, 2022

End Date

November 4, 2024

Last Updated

4 months ago

Study Type

Observational

Sex

All

Investigators

Sponsor

H. Lee Moffitt Cancer Center and Research Institute

Responsible Party

Sponsor

Eligibility Criteria

Inclusion Criteria

•Patients with Stage IV Renal Cell Carcinoma
•Within 3 weeks from starting combination immune checkpoint blockade with tyrosine kinase inhibitor or multikinase inhibitor
•Estimated survival of 6 months or more
•Able to read and speak English

Exclusion Criteria

•Unable to read or speak English
•Enrolled in another clinical trial

Outcomes

Primary Outcomes

Acceptability of Smart Phone Application

Time Frame: at 6 months

Patient's acceptability of the smart phone application for education will be captured in the patient post education survey.

Secondary Outcomes

Efficacy of Smart Phone Application -Quality of Life(at 6 months)
Efficacy of Smart Phone Application - Patient Knowledge(Weekly, beginning at baseline to month 6)